OBJECTIVES: The aim of the study was to analyze use of ACE inhibitors in Serbia compared with Montenegro in year 2009. METHODS: Data about use of ACE inhibitors in Serbia and in Montenegro in 2009 taken from Republic Institute for Health Insurance from Serbia and from Health Service Fund of Montenegero. RESULTS: Use of ACE inhibitors in Serbia in 2009 was 179,26 DDD/1000 inh/day and in Montenegro was 83,32 DDD/1000 inh/day. In Serbia 5.977.289,00€ has been spent for ACE inhibitors and in Montenegro 2.488.464,95€ in the same year. In Serbia on the first place is enalapril with 78,32 DDD/1000 inh/day or 44,43%, on the second place fosinopril with 20,09 DDD/1000 inh/day or 11,40%, while on the third place is ramipril with 19,11 DDD/1000 inh/day or 10,84% of total drug utilization in this subgroup. Amount spent on enalapril was 1.717.416,00€ or 28,73%, on fosinopril 1.116.972,00€ or 18,69%, and on ramipril 470.937,00€ or 7,88% of total finances spent on this subgroup C09 in year 2009. In Montenegro on the first place are lisinopril and hydrochlorothiazide with 19,62 DDD/1000 inh/day or 23,55%, on the second place are fosinopril and hydrochlorothiazide with 12,77 DDD/1000 inh/day or 15,33%, while on the third place is fosinopril with 11,92 DDD/1000 inh/day or 14,31% of total drug utilization inside this subgroup. Money spent on lisinopril and hydrochlorothiazide are 425.547,30€ or 17,10%, on fosinopril and hydrochlorothiazide 762.333,74€ or 30,63%, and on fosinopril 533.307,43€ or 21,43% of total finances spent on this subgroup C09 in the year 2009. CONCLUSIONS: Comparing the consumption of ACE inhibitors in Serbia and Montenegro in the year 2009, it becomes clear that the combination of ACE inhibitors with diuretics is most frequently used in Montenegro, while in Serbia the use of this combination is on the the fifth place in this group of drugs.